Cancer is one of the leading causes of death worldwide.1 With more than 100 types and a biology that’s constantly changing, it’s also one of the most complex diseases known to mankind.2, 3 In 2012, there were 14.1 million new cancer cases and 8.2 million cancer deaths worldwide.4 By 2030, the global burden is expected to grow to 21.7 million new cancer cases and 13 million cancer deaths as a result of growth and aging of the population.5
Oncology Breakthroughs: The Latest in Cancer Research
Pfizer strives to set the standard in cancer research. Through clinical cancer research we create results for oncology treatment options.
Pfizer is developing treatments that are as diverse as the disease itself with a sharp focus on the most disruptive advances in science and guided by the urgency to help patients receive the next wave of life-changing cancer medicines.
Although traditional cancer-fighting tools like chemotherapy and radiation remain important treatment options for doctors and patients, scientists are uncovering new approaches to attack cancer cells directly and more effectively. With recent clinical success in immunotherapy reshaping the field of oncology, the prospects for more durable and even curative responses to many cancers are on the horizon.
Pfizer Scientist Bob Abraham Meets Patient Matt Hiznay
The key to cancer treatment is not just to understand how cancer cells behave on their own, but to learn how they evade the body’s immune system and existing treatments. Pfizer’s pipeline of potential cancer medicines includes differentiated therapies with multiple mechanisms of action that target both the tumor itself and the immune system. We are investigating medicines for breast cancer, non-small cell lung cancer, gastric cancer, ovarian cancer, renal cell carcinoma, and hematologic malignancies, including leukemias and lymphomas.
Our research in oncology focuses primarily on:
Pfizer is advancing the frontiers of cancer biology with a “toolbox” of differentiated modalities that will allow us to provide the right treatment for each patient:
Cancer is a challenge far too great to tackle alone. Collaborations are a key part of how Pfizer conducts cancer research. We look to partner with the strongest science and scientists wherever it is found, be it academia, government, foundations, biotechnology or other large pharmaceutical companies.
Work with Us
If you’re interested in collaborating with our Oncology Partnering page to learn more about the work we're pursuing.